[go: up one dir, main page]

HUE067333T2 - Prefúziós RSV F fehérjék és ezek felhasználása - Google Patents

Prefúziós RSV F fehérjék és ezek felhasználása

Info

Publication number
HUE067333T2
HUE067333T2 HUE14775224A HUE14775224A HUE067333T2 HU E067333 T2 HUE067333 T2 HU E067333T2 HU E14775224 A HUE14775224 A HU E14775224A HU E14775224 A HUE14775224 A HU E14775224A HU E067333 T2 HUE067333 T2 HU E067333T2
Authority
HU
Hungary
Prior art keywords
proteins
prefusion rsv
prefusion
rsv
Prior art date
Application number
HUE14775224A
Other languages
English (en)
Inventor
Jeffrey Boyington
Ivelin Georgiev
Marie Pancera
Cinque Soto
Sanjay Srivatsan
Guillaume Stewart-Jones
Peter Kwong
Barney Graham
Jason Mclellan
Michael Joyce
Masaru Kanekiyo
Baoshan Zhang
Lei Chen
Man Chen
Gwo-Yu Chuang
Jason Gorman
Yongping Yang
Tongqing Zhou
Mallika Sastry
Gilad Ofek
Original Assignee
The United States Of America As Represented By
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by The United States Of America As Represented By filed Critical The United States Of America As Represented By
Publication of HUE067333T2 publication Critical patent/HUE067333T2/hu

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/155—Paramyxoviridae, e.g. parainfluenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C07K14/08—RNA viruses
    • C07K14/115—Paramyxoviridae, e.g. parainfluenza virus
    • C07K14/135—Respiratory syncytial virus
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/564—Immunoassay; Biospecific binding assay; Materials therefor for pre-existing immune complex or autoimmune disease, i.e. systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, rheumatoid factors or complement components C1-C9
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5252—Virus inactivated (killed)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5254—Virus avirulent or attenuated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A61K2039/543—Mucosal route intranasal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
    • C07K2319/21—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a His-tag
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
    • C07K2319/22—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a Strep-tag
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/50—Fusion polypeptide containing protease site
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/735—Fusion polypeptide containing domain for protein-protein interaction containing a domain for self-assembly, e.g. a viral coat protein (includes phage display)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18511—Pneumovirus, e.g. human respiratory syncytial virus
    • C12N2760/18522—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18511—Pneumovirus, e.g. human respiratory syncytial virus
    • C12N2760/18523—Virus like particles [VLP]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18511—Pneumovirus, e.g. human respiratory syncytial virus
    • C12N2760/18534—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Pulmonology (AREA)
  • Urology & Nephrology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Rheumatology (AREA)
  • Cell Biology (AREA)
  • Rehabilitation Therapy (AREA)
  • Food Science & Technology (AREA)
HUE14775224A 2013-03-13 2014-03-13 Prefúziós RSV F fehérjék és ezek felhasználása HUE067333T2 (hu)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201361780910P 2013-03-13 2013-03-13
US201361798389P 2013-03-15 2013-03-15
US201361857613P 2013-07-23 2013-07-23
US201361863909P 2013-08-09 2013-08-09

Publications (1)

Publication Number Publication Date
HUE067333T2 true HUE067333T2 (hu) 2024-10-28

Family

ID=51625430

Family Applications (1)

Application Number Title Priority Date Filing Date
HUE14775224A HUE067333T2 (hu) 2013-03-13 2014-03-13 Prefúziós RSV F fehérjék és ezek felhasználása

Country Status (21)

Country Link
US (4) US10017543B2 (hu)
EP (2) EP4421177A3 (hu)
JP (4) JP6703475B2 (hu)
KR (2) KR102766946B1 (hu)
CN (2) CN105473604B (hu)
AU (4) AU2014243756B2 (hu)
CA (1) CA2902877A1 (hu)
DK (1) DK2970398T3 (hu)
ES (1) ES2981623T3 (hu)
FI (1) FI2970398T3 (hu)
HR (1) HRP20240996T1 (hu)
HU (1) HUE067333T2 (hu)
LT (1) LT2970398T (hu)
MX (2) MX2015013065A (hu)
PL (1) PL2970398T3 (hu)
PT (1) PT2970398T (hu)
RS (1) RS65760B1 (hu)
RU (2) RU2021132097A (hu)
SI (1) SI2970398T1 (hu)
SM (1) SMT202400297T1 (hu)
WO (1) WO2014160463A1 (hu)

Families Citing this family (136)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080124355A1 (en) 2006-09-22 2008-05-29 David Gordon Bermudes Live bacterial vaccines for viral infection prophylaxis or treatment
US20110229471A1 (en) 2008-11-26 2011-09-22 Cedars-Sinai Medical Center Methods of determining responsiveness to anti-tnf alpha therapy in inflammatory bowel disease
WO2014121021A1 (en) 2013-02-01 2014-08-07 Medimmune, Llc Respiratory syncytial virus f protein epitopes
US9738689B2 (en) * 2013-03-13 2017-08-22 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Prefusion RSV F proteins and their use
HUE067333T2 (hu) * 2013-03-13 2024-10-28 The United States Of America As Represented By Prefúziós RSV F fehérjék és ezek felhasználása
AU2014239583B2 (en) 2013-03-14 2020-07-02 Children's Healthcare Of Atlanta, Inc. Recombinant RSV with silent mutations, vaccines, and methods related thereto
JP6671276B2 (ja) 2013-03-27 2020-03-25 セダーズ−シナイ メディカル センター Ｔｌ１ａ機能および関連するシグナル経路の抑制による線維症および炎症の緩和および回復
JP6469081B2 (ja) 2013-04-25 2019-02-13 ヤンセン ファッシンズ アンド プリベンション ベーフェーＪａｎｓｓｅｎ Ｖａｃｃｉｎｅｓ ＆ Ｐｒｅｖｅｎｔｉｏｎ Ｂ．Ｖ． 安定化された可溶性融合前ｒｓｖｆポリペプチド
BR112015031509B1 (pt) * 2013-06-17 2023-05-09 Janssen Vaccines & Prevention B.V. Polipeptídeo de fusão (f) do vírus sincicial respiratório (rsv) pré- fusão recombinante e composição que o compreende
EP4105236A1 (en) 2013-07-19 2022-12-21 Cedars-Sinai Medical Center Anti-tl1a (tnfsf15) antibody for treatment of inflammatory bowel disease
WO2015013551A1 (en) 2013-07-25 2015-01-29 Marshall Christopher Patrick Conformationally stabilized rsv pre-fusion f proteins
KR20160044566A (ko) 2013-08-21 2016-04-25 큐어백 아게 호흡기 세포융합 바이러스
JP2016533332A (ja) * 2013-09-24 2016-10-27 マサチューセッツ インスティテュート オブ テクノロジー 自己集合型ナノ粒子ワクチン
US9630994B2 (en) 2014-11-03 2017-04-25 University Of Washington Polypeptides for use in self-assembling protein nanostructures
CA2974359A1 (en) 2015-01-20 2016-07-28 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Recombinant parainfluenza virus expressing a chimeric f protein and uses thereof
CN107405393A (zh) 2015-01-29 2017-11-28 新加坡科技研究局 携带基孔肯亚相关肽的纳米胶囊
AU2016289492B2 (en) * 2015-07-07 2022-08-11 Janssen Vaccines & Prevention B.V. Vaccine against RSV
CN107847581B (zh) 2015-07-07 2022-03-22 扬森疫苗与预防公司 稳定化的可溶性融合前rsv f多肽
FR3041962B1 (fr) * 2015-10-01 2018-01-05 Lab Francais Du Fractionnement Procede d'enrichissement d'une preparation d'immunoglobulines en immunoglobulines anti-rsv et preparation ainsi enrichie
MA47016A (fr) 2015-10-22 2018-08-29 Modernatx Inc Vaccins contre les virus respiratoires
BR112018008102A2 (pt) * 2015-10-22 2018-11-06 Modernatx Inc vacina de vírus sincicial respiratório
MX2018005462A (es) 2015-10-29 2018-08-01 Univ Emory Composiciones inmunogénicas de rsv quimérico y métodos de uso.
AU2016379097C1 (en) * 2015-12-23 2021-04-08 Pfizer Inc. RSV F protein mutants
KR20240095481A (ko) 2016-03-17 2024-06-25 세다르스-신나이 메디칼 센터 Rnaset2를 통한 염증성 장 질환의 진단 방법
CN115960263A (zh) * 2016-03-29 2023-04-14 美国政府(由卫生和人类服务部的部长所代表) 取代修饰的融合前rsv f蛋白及其用途
AU2017248018A1 (en) 2016-04-05 2018-09-27 Janssen Vaccines & Prevention B.V. Vaccine against RSV
CN109069616A (zh) 2016-04-05 2018-12-21 扬森疫苗与预防公司 稳定化的可溶性融合前rsv f蛋白
IL245059A0 (en) 2016-04-12 2016-06-30 Technion Res & Dev Foundation Electrospun scaffolds from extracellular matrix
WO2017207480A1 (en) 2016-05-30 2017-12-07 Janssen Vaccines & Prevention B.V. Stabilized pre-fusion rsv f proteins
EP3474893A1 (en) 2016-06-27 2019-05-01 The U.S.A. as represented by the Secretary, Department of Health and Human Services Self-assembling insect ferritin nanoparticles for display of co-assembled trimeric antigens
CN106119287B (zh) * 2016-08-29 2019-10-11 广东华南疫苗股份有限公司 一种表达呼吸道合胞病毒f蛋白的重组载体及方法
WO2018067300A1 (en) * 2016-10-03 2018-04-12 University Of Massachusetts Methods for immunizing pre-immune subjects against respiratory syncytial virus (rsv)
EP4234027A3 (en) 2016-10-25 2023-12-06 The U.S.A. as represented by the Secretary, Department of Health and Human Services Prefusion piv f immunogens and their use
SG11201903737PA (en) 2016-10-26 2019-05-30 Cedars Sinai Medical Center Neutralizing anti-tl1a monoclonal antibodies
TWI683826B (zh) * 2016-11-22 2020-02-01 國立臺灣大學 重組ｒｓｖ抗原
US11129906B1 (en) 2016-12-07 2021-09-28 David Gordon Bermudes Chimeric protein toxins for expression by therapeutic bacteria
US11180535B1 (en) 2016-12-07 2021-11-23 David Gordon Bermudes Saccharide binding, tumor penetration, and cytotoxic antitumor chimeric peptides from therapeutic bacteria
EP3551193A4 (en) 2016-12-08 2020-08-19 Modernatx, Inc. NUCLEIC ACID VACCINES AGAINST RESPIRATORY VIRUSES
CA3043790A1 (en) 2016-12-16 2018-06-21 Institute For Research In Biomedicine Novel recombinant prefusion rsv f proteins and uses thereof
GB201621686D0 (en) 2016-12-20 2017-02-01 Glaxosmithkline Biologicals Sa Novel methods for inducing an immune response
CN108265079A (zh) * 2017-01-02 2018-07-10 刘昕 一种新型呼吸道合胞体病毒pre-F融合蛋白载体的制备方法
MA47787A (fr) 2017-03-15 2020-01-22 Modernatx Inc Vaccin contre le virus respiratoire syncytial
WO2018175518A1 (en) * 2017-03-22 2018-09-27 The Scripps Research Institute Mini-protein immunogens displayng neutralization epitopes for respiratory syncytial virus (rsv)
CA3058794A1 (en) 2017-04-04 2018-10-11 University Of Washington Self-assembling protein nanostructures displaying paramyxovirus and/or pneumovirus f proteins and their use
JP2020519663A (ja) 2017-05-17 2020-07-02 ヤンセン ファッシンズ アンド プリベンション ベーフェーＪａｎｓｓｅｎ Ｖａｃｃｉｎｅｓ ＆ Ｐｒｅｖｅｎｔｉｏｎ Ｂ．Ｖ． Ｒｓｖ感染に対する防御免疫を誘導するための方法及び組成物
IE87439B1 (en) 2017-05-30 2023-10-11 Glaxosmithkline Biologicals Sa Novel methods for manufacturing an adjuvant
US11680085B2 (en) * 2017-06-14 2023-06-20 Virometix Ag Cyclic peptides for protection against respiratory syncytial virus
CN111405907B (zh) * 2017-08-07 2024-10-01 考尔德生物科技有限公司 构象稳定的rsv预融合f蛋白
EP3681533A1 (en) 2017-09-15 2020-07-22 Janssen Vaccines & Prevention B.V. Method for the safe induction of immunity against rsv
JP2019092481A (ja) * 2017-11-27 2019-06-20 国立大学法人東京工業大学 ヘテロタンパク質ケージ
MX2020005481A (es) 2017-12-01 2020-12-07 Glaxosmithkline Biologicals Sa Purificacion de saponina.
AU2019212237B2 (en) 2018-01-29 2024-12-12 Merck Sharp & Dohme Llc Stabilized RSV F proteins and uses thereof
MA54676A (fr) 2018-01-29 2021-11-17 Modernatx Inc Vaccins à base d'arn contre le vrs
EP3758747A1 (en) 2018-02-28 2021-01-06 University of Washington Self-asssembling nanostructure vaccines
US11623004B2 (en) 2018-03-16 2023-04-11 University Of Pittsburgh Of The Commonwealth System Of Higher Education Compositions and methods for vaccination against respiratory syncytial virus infection
EP3773698A1 (en) 2018-04-03 2021-02-17 Sanofi Ferritin proteins
JP7614842B2 (ja) 2018-04-03 2025-01-16 サノフイ 抗原性エプスタインバーウイルスポリペプチド
AU2019247034A1 (en) * 2018-04-03 2020-10-22 Sanofi Antigenic respiratory syncytial virus polypeptides
WO2019195284A1 (en) * 2018-04-03 2019-10-10 Sanofi Antigenic influenza-ferritin polypeptides
US20210170017A1 (en) 2018-04-17 2021-06-10 Curevac Ag Novel rsv rna molecules and compositions for vaccination
US20210070871A1 (en) 2018-04-25 2021-03-11 Prometheus Biosciences, Inc. Optimized anti-tl1a antibodies
IL278418B2 (en) 2018-05-04 2024-01-01 Spybiotech Ltd A vaccine
CN110684747B (zh) * 2018-07-06 2024-05-24 厦门大学 灭活及保存呼吸道合胞病毒的方法
BR112020027090A2 (pt) 2018-07-31 2021-03-30 Glaxosmithkline Biologicals S.A. Método de purificação de antígenos
EP3829631A1 (en) 2018-08-03 2021-06-09 The United States of America, as represented by The Secretary, Department of Health and Human Services Nipah virus immunogens and their use
CA3107077A1 (en) 2018-08-07 2020-02-13 Glaxosmithkline Biologicals Sa Processes and vaccines
CN113164583A (zh) * 2018-11-13 2021-07-23 扬森疫苗与预防公司 稳定的融合前rsv f蛋白
WO2020102603A1 (en) * 2018-11-14 2020-05-22 Rubryc Therapeutics, Inc. Engineered cd25 polypeptides and uses thereof
US11351242B1 (en) 2019-02-12 2022-06-07 Modernatx, Inc. HMPV/hPIV3 mRNA vaccine composition
CA3130433A1 (en) 2019-02-28 2020-09-03 Km Biologics Co., Ltd. Rsv f/g chimeric vaccine
WO2020245207A1 (en) 2019-06-05 2020-12-10 Glaxosmithkline Biologicals Sa Saponin purification
JP2022546813A (ja) 2019-09-04 2022-11-09 ユニヴァーシティ オブ ワシントン パラミクソウイルスおよび／またはニューモウイルスのｆタンパク質を提示する自己組織化タンパク質ナノ構造体ならびにその使用
JP7504992B2 (ja) 2019-10-24 2024-06-24 プロメテウス バイオサイエンシーズ，インク． Ｔｎｆ様リガンド１ａ（ｔｌ１ａ）に対するヒト化抗体およびその使用
IL293666A (en) 2019-12-11 2022-08-01 Us Health Mumps and measles virus immunogens and their use
US20230086093A1 (en) * 2019-12-23 2023-03-23 Mitsubishi Tanabe Pharma Corporation Mutant rsv f protein and use thereof
US10953089B1 (en) 2020-01-27 2021-03-23 Novavax, Inc. Coronavirus vaccine formulations
AU2021214774A1 (en) * 2020-01-30 2022-08-25 Modernatx, Inc. Respiratory virus immunizing compositions
US12194089B2 (en) 2020-02-04 2025-01-14 CureVac SE Coronavirus vaccine
EP4142785A2 (en) * 2020-04-29 2023-03-08 The United States of America, as represented by the Secretary, Department of Health and Human Services Recombinant human metapneumovirus f proteins and their use
EP4157345A4 (en) * 2020-05-29 2024-09-11 Board of Regents, The University of Texas System GENETICALLY MODIFIED CORONAVIRUS SPIKE(S) PROTEIN AND METHODS OF USE THEREOF
AU2021279312A1 (en) * 2020-05-29 2022-12-15 CureVac SE Nucleic acid based combination vaccines
JP2022023814A (ja) 2020-07-27 2022-02-08 ファイザー・インク 組換え生産された三量体型のｒｓｖタンパク質の精製方法
JP2022023813A (ja) 2020-07-27 2022-02-08 ファイザー・インク 組換え生産されたｒｓｖタンパク質の精製方法における陰イオン交換クロマトグラフィー用洗浄溶液の改良
CN112226444B (zh) * 2020-08-25 2022-11-04 北京交通大学 呼吸道合胞病毒全长融合前融合糖蛋白核苷酸序列、重组腺病毒载体及其应用产品
JP2022060169A (ja) 2020-10-02 2022-04-14 ファイザー・インク Ｒｓｖ ｆタンパク質生産のための細胞培養工程
AU2021357826A1 (en) 2020-10-09 2023-05-11 Board Of Regents, The University Of Texas System Prefusion-stabilized hmpv f proteins
CA3199937A1 (en) 2020-10-28 2022-05-05 Sanofi Pasteur Liposomes containing tlr4 agonist, preparation and uses thereof
CN112592928B (zh) * 2020-12-31 2021-08-31 北京鼎成肽源生物技术有限公司 冠状病毒的融合基因、融合蛋白、重组载体、通用型dc疫苗及其制备方法
KR20230147156A (ko) * 2021-02-19 2023-10-20 얀센 백신스 앤드 프리벤션 비.브이. 안정화된 융합 전 rsv fb 항원
AU2022251938A1 (en) 2021-04-02 2023-11-16 Bureau D’Études Biologiques Scientifiques Et Médicales IMMUNOGENIC COMPOSITION CONTAINING AN ANTIGEN AND AN ADJUVANT COMPRISING AL-MOFs
US20220324917A1 (en) * 2021-04-12 2022-10-13 Sk Bioscience Co., Ltd. Recombinant rsv live vaccine strain and the preparing method thereof
WO2022221159A1 (en) * 2021-04-15 2022-10-20 Merck Sharp & Dohme Llc Rotavirus vectors for heterologous gene delivery
US20240350616A1 (en) * 2021-08-10 2024-10-24 Icosavax, Inc. Virus-like particle vaccine for respiratory syncytial virus
JP2024536236A (ja) * 2021-09-29 2024-10-04 エスケー バイオサイエンス カンパニー リミテッド 組み換えられた弱毒化ｒｓｖ生ワクチン及びその製造方法
WO2023208206A1 (zh) * 2022-04-29 2023-11-02 北京新合睿恩生物医疗科技有限公司 Rsv f蛋白突变体及其应用
KR20250021328A (ko) * 2022-05-31 2025-02-12 브이엘피 테라퓨틱스 재팬 가부시키가이샤 수정된 백신 설계 개발
WO2023237649A1 (en) * 2022-06-10 2023-12-14 Glaxosmithkline Biologicals Sa Rsv vaccination with trimeric rsv f fusion protein
WO2024041772A1 (en) * 2022-08-22 2024-02-29 Glaxosmithkline Biologicals Sa Rsv-f proteins
WO2024069420A2 (en) 2022-09-29 2024-04-04 Pfizer Inc. Immunogenic compositions comprising an rsv f protein trimer
CN116478296B (zh) * 2022-10-17 2024-02-23 厦门大学 截短的呼吸道合胞病毒f蛋白及其用途
WO2024089633A1 (en) 2022-10-27 2024-05-02 Pfizer Inc. Rna molecules encoding rsv-f and vaccines containing them
WO2024089634A1 (en) 2022-10-27 2024-05-02 Pfizer Inc. Immunogenic compositions against influenza and rsv
TW202434283A (zh) * 2022-11-04 2024-09-01 法商賽諾菲公司 呼吸道融合病毒rna疫苗接種
WO2024100196A1 (en) * 2022-11-09 2024-05-16 Nykode Therapeutics ASA Co-expression of constructs and polypeptides
KR102531775B1 (ko) 2022-11-11 2023-05-15 대한민국 Rsv f 항체 또는 이의 항원 결합 단편
CN116284266B (zh) * 2022-11-21 2024-01-19 怡道生物科技(苏州)有限公司 突变型呼吸道合胞病毒融合前f蛋白及其应用
WO2024115561A1 (en) * 2022-12-01 2024-06-06 Glaxosmithkline Biologicals Sa Vaccination against rsv
US20240252612A1 (en) 2022-12-11 2024-08-01 Pfizer Inc. Immunogenic compositions and uses thereof
WO2024155561A2 (en) * 2023-01-17 2024-07-25 The Scripps Research Institute Engineered paramyxovirus soluble fusion (f) proteins and related vaccines
US20240252614A1 (en) 2023-01-18 2024-08-01 Pfizer Inc. Vaccines against respiratory diseases
WO2024164020A2 (en) * 2023-02-03 2024-08-08 The Trustees Of Columbia University In The City Of New York Methods of inhibiting paramyxoviridae fusion to a target cell
WO2024175579A1 (en) * 2023-02-21 2024-08-29 Janssen Vaccines & Prevention B.V. Stabilized trimeric rsv fusion proteins without a heterologous trimerzation domain
WO2024175040A1 (en) * 2023-02-22 2024-08-29 Everest Medicines (China) Co., Ltd. RSV mRNA VACCINES
WO2024193380A1 (zh) * 2023-03-17 2024-09-26 成都威斯克生物医药有限公司 抗呼吸道合胞病毒感染的疫苗
CN116536357A (zh) * 2023-04-17 2023-08-04 中国医学科学院输血研究所 构建CRISPR/Cas12a中sgRNA剪切活性筛选系统的方法
CN118108812A (zh) * 2023-05-04 2024-05-31 国药中生生物技术研究院有限公司 Rsv f蛋白的突变体
CN118994329A (zh) * 2023-05-18 2024-11-22 北京微星生物科技有限公司 融合前rsv f蛋白及其应用
WO2024241172A2 (en) 2023-05-19 2024-11-28 Glaxosmithkline Biologicals Sa Methods for eliciting an immune response to respiratory syncycial virus and streptococcus pneumoniae infection
CN117050149A (zh) * 2023-05-19 2023-11-14 珠海丽凡达生物技术有限公司 包含人呼吸道合胞病毒抗原的免疫组合物及其制备方法和应用
CN119019514A (zh) * 2023-05-25 2024-11-26 江苏瑞科生物技术股份有限公司 一种具有免疫原性的呼吸道合胞病毒（rsv）多肽
WO2024251281A1 (zh) * 2023-06-07 2024-12-12 四川三叶草生物制药有限公司 Rsv疫苗组合物、方法及其用途
WO2024256637A1 (en) * 2023-06-16 2024-12-19 Glaxosmithkline Biologicals Sa Cysteine-substituted rsv-f proteins
WO2025012756A1 (en) 2023-07-07 2025-01-16 Pfizer Inc. Amphiphilic tlr7/8 adjuvants and uses thereof
CN119431524A (zh) * 2023-08-07 2025-02-14 北京新合睿恩生物医疗科技有限公司 Rsv融合前构象f蛋白的突变体及其应用
CN117304278B (zh) * 2023-11-28 2024-04-16 江苏瑞科生物技术股份有限公司 一种重组rsv f蛋白及其应用
CN117567652B (zh) * 2024-01-19 2024-05-14 北京安百胜生物科技有限公司 一种重组呼吸道合胞病毒颗粒抗原
CN117586359A (zh) * 2024-01-19 2024-02-23 北京安百胜生物科技有限公司 一种具有免疫原性的呼吸道合胞病毒（rsv）多肽
CN117586357B (zh) * 2024-01-19 2024-07-09 北京安百胜生物科技有限公司 一种具有免疫原性的呼吸道合胞病毒（rsv）多肽
CN117586425B (zh) * 2024-01-19 2024-06-14 北京安百胜生物科技有限公司 一种重组呼吸道合胞病毒颗粒抗原其制备方法和应用
CN118440937B (zh) * 2024-04-09 2025-02-25 嘉译生物医药(杭州)有限公司 新型的人合胞病毒RSV B mRNA疫苗
CN118580323A (zh) * 2024-05-22 2024-09-03 苏州聚微生物科技有限公司 Rsv融合前f蛋白的突变体及其制备和应用
CN118406159A (zh) * 2024-05-22 2024-07-30 苏州聚微生物科技有限公司 RSV pre-F截短体及其生产方法和应用
CN118496324A (zh) * 2024-05-22 2024-08-16 苏州聚微生物科技有限公司 RSV pre-F突变体及其生产方法和用途
CN119074910A (zh) * 2024-08-30 2024-12-06 中国医学科学院病原生物学研究所 以麻疹减毒活疫苗为载体的重组呼吸道合胞病毒疫苗及其制备方法
CN119176859A (zh) * 2024-11-26 2024-12-24 北京成大天和生物科技有限公司 呼吸道合胞病毒f蛋白突变体及其应用
CN119371496A (zh) * 2024-12-26 2025-01-28 北京华诺泰生物医药科技有限公司 一种呼吸道合胞病毒f蛋白突变体及其应用

Family Cites Families (109)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US472209A (en) 1892-04-05 Vacuum-pan
US4235871A (en) 1978-02-24 1980-11-25 Papahadjopoulos Demetrios P Method of encapsulating biologically active materials in lipid vesicles
US4235877A (en) 1979-06-27 1980-11-25 Merck & Co., Inc. Liposome particle containing viral or bacterial antigenic subunit
US4372945A (en) 1979-11-13 1983-02-08 Likhite Vilas V Antigen compounds
US4675189A (en) 1980-11-18 1987-06-23 Syntex (U.S.A.) Inc. Microencapsulation of water soluble active polypeptides
IL61904A (en) 1981-01-13 1985-07-31 Yeda Res & Dev Synthetic vaccine against influenza virus infections comprising a synthetic peptide and process for producing same
US4722848A (en) 1982-12-08 1988-02-02 Health Research, Incorporated Method for immunizing animals with synthetically modified vaccinia virus
US4436727A (en) 1982-05-26 1984-03-13 Ribi Immunochem Research, Inc. Refined detoxified endotoxin product
US4866034A (en) 1982-05-26 1989-09-12 Ribi Immunochem Research Inc. Refined detoxified endotoxin
SE8205892D0 (sv) 1982-10-18 1982-10-18 Bror Morein Immunogent membranproteinkomplex, sett for framstellning och anvendning derav som immunstimulerande medel och sasom vaccin
US4501728A (en) 1983-01-06 1985-02-26 Technology Unlimited, Inc. Masking of liposomes from RES recognition
JPS60100516A (ja) 1983-11-04 1985-06-04 Takeda Chem Ind Ltd 徐放型マイクロカプセルの製造法
US4957735A (en) 1984-06-12 1990-09-18 The University Of Tennessee Research Corporation Target-sensitive immunoliposomes- preparation and characterization
CA1256638A (en) 1984-07-06 1989-06-27 Motoaki Tanaka Polymer and its production
US5019369A (en) 1984-10-22 1991-05-28 Vestar, Inc. Method of targeting tumors in humans
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
JP2551756B2 (ja) 1985-05-07 1996-11-06 武田薬品工業株式会社 ポリオキシカルボン酸エステルおよびその製造法
US4707543A (en) 1985-09-17 1987-11-17 The United States Of America As Represented By The Secretary Of The Army Process for the preparation of detoxified polysaccharide-outer membrane protein complexes, and their use as antibacterial vaccines
US5091309A (en) 1986-01-16 1992-02-25 Washington University Sindbis virus vectors
US4877611A (en) 1986-04-15 1989-10-31 Ribi Immunochem Research Inc. Vaccine containing tumor antigens and adjuvants
US4902505A (en) 1986-07-30 1990-02-20 Alkermes Chimeric peptides for neuropeptide delivery through the blood-brain barrier
US4837028A (en) 1986-12-24 1989-06-06 Liposome Technology, Inc. Liposomes with enhanced circulation time
CA1331443C (en) 1987-05-29 1994-08-16 Charlotte A. Kensil Saponin adjuvant
US5057540A (en) 1987-05-29 1991-10-15 Cambridge Biotech Corporation Saponin adjuvant
US5726292A (en) 1987-06-23 1998-03-10 Lowell; George H. Immuno-potentiating systems for preparation of immunogenic materials
US5004697A (en) 1987-08-17 1991-04-02 Univ. Of Ca Cationized antibodies for delivery through the blood-brain barrier
US5278302A (en) 1988-05-26 1994-01-11 University Patents, Inc. Polynucleotide phosphorodithioates
US4912094B1 (en) 1988-06-29 1994-02-15 Ribi Immunochem Research Inc. Modified lipopolysaccharides and process of preparation
CA1336955C (en) * 1988-09-20 1995-09-12 Peter R. Paradiso Respiratory syncytial virus: vaccines and diagnostic assays
US5217879A (en) 1989-01-12 1993-06-08 Washington University Infectious Sindbis virus vectors
US5055303A (en) 1989-01-31 1991-10-08 Kv Pharmaceutical Company Solid controlled release bioadherent emulsions
US5703055A (en) 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
US5271961A (en) 1989-11-06 1993-12-21 Alkermes Controlled Therapeutics, Inc. Method for producing protein microspheres
US5188837A (en) 1989-11-13 1993-02-23 Nova Pharmaceutical Corporation Lipsopheres for controlled delivery of substances
US5268164A (en) 1990-04-23 1993-12-07 Alkermes, Inc. Increasing blood-brain barrier permeability with permeabilizer peptides
US5254342A (en) 1991-09-30 1993-10-19 University Of Southern California Compositions and methods for enhanced transepithelial and transendothelial transport or active agents
US5643578A (en) 1992-03-23 1997-07-01 University Of Massachusetts Medical Center Immunization by inoculation of DNA transcription unit
ATE154240T1 (de) 1992-03-12 1997-06-15 Alkermes Inc Acth enthaltende mikrokugeln mit gesteuerter abgabe
US5534496A (en) 1992-07-07 1996-07-09 University Of Southern California Methods and compositions to enhance epithelial drug transport
DE69332485T2 (de) 1992-08-11 2003-11-13 The President And Fellows Of Harvard College, Cambridge Immunmodulierende peptide
US5593972A (en) 1993-01-26 1997-01-14 The Wistar Institute Genetic immunization
ATE204762T1 (de) 1993-03-23 2001-09-15 Smithkline Beecham Biolog 3-0-deazylierte monophosphoryl lipid a enthaltende impfstoff-zusammensetzungen
FR2705686B1 (fr) 1993-05-28 1995-08-18 Transgene Sa Nouveaux adénovirus défectifs et lignées de complémentation correspondantes.
ES2310924T3 (es) 1993-07-13 2009-01-16 Centelion Vectores adenovirales defectivos y utilizacion en terapia genica.
US5514670A (en) 1993-08-13 1996-05-07 Pharmos Corporation Submicron emulsions for delivery of peptides
US5961970A (en) 1993-10-29 1999-10-05 Pharmos Corporation Submicron emulsions as vaccine adjuvants
EP0729473B1 (en) 1993-11-17 2000-08-23 OM Pharma Glucosamine disaccharides, method for their preparation, pharmaceutical composition comprising same, and their use
WO1995016772A1 (en) 1993-12-14 1995-06-22 Cornell Research Foundation, Inc. Adenovirus gene expression system
WO1995026204A1 (en) 1994-03-25 1995-10-05 Isis Pharmaceuticals, Inc. Immune stimulation by phosphorothioate oligonucleotide analogs
US5851806A (en) 1994-06-10 1998-12-22 Genvec, Inc. Complementary adenoviral systems and cell lines
EP0784690B1 (en) 1994-06-10 2006-08-16 Genvec, Inc. Complementary adenoviral vector systems and cell lines
DE69535905D1 (de) 1994-07-15 2009-02-26 Coley Pharm Group Inc Immunomodulatorische Oligonukleotide
AUPM873294A0 (en) 1994-10-12 1994-11-03 Csl Limited Saponin preparations and use thereof in iscoms
IL116816A (en) 1995-01-20 2003-05-29 Rhone Poulenc Rorer Sa Cell for the production of a defective recombinant adenovirus or an adeno-associated virus and the various uses thereof
UA56132C2 (uk) 1995-04-25 2003-05-15 Смітклайн Бічем Байолоджікалс С.А. Композиція вакцини (варіанти), спосіб стабілізації qs21 відносно гідролізу (варіанти), спосіб приготування композиції вакцини
US5837511A (en) 1995-10-02 1998-11-17 Cornell Research Foundation, Inc. Non-group C adenoviral vectors
US5666153A (en) 1995-10-03 1997-09-09 Virtual Shopping, Inc. Retractable teleconferencing apparatus
US6020182A (en) 1996-07-12 2000-02-01 Connaught Laboratories Limited Subunit respiratory syncytial virus vaccine preparation
US5856462A (en) 1996-09-10 1999-01-05 Hybridon Incorporated Oligonucleotides having modified CpG dinucleosides
US6303347B1 (en) 1997-05-08 2001-10-16 Corixa Corporation Aminoalkyl glucosaminide phosphate compounds and their use as adjuvants and immunoeffectors
US6764840B2 (en) 1997-05-08 2004-07-20 Corixa Corporation Aminoalkyl glucosaminide phosphate compounds and their use as adjuvants and immunoeffectors
US6113918A (en) 1997-05-08 2000-09-05 Ribi Immunochem Research, Inc. Aminoalkyl glucosamine phosphate compounds and their use as adjuvants and immunoeffectors
GB9727262D0 (en) 1997-12-24 1998-02-25 Smithkline Beecham Biolog Vaccine
AU7833298A (en) * 1998-06-10 1999-12-30 Incyte Pharmaceuticals, Inc. New human carboxypeptidase inhibitor
US6113913A (en) 1998-06-26 2000-09-05 Genvec, Inc. Recombinant adenovirus
US20040006242A1 (en) 1999-02-01 2004-01-08 Hawkins Lynn D. Immunomodulatory compounds and method of use thereof
US6551600B2 (en) 1999-02-01 2003-04-22 Eisai Co., Ltd. Immunological adjuvant compounds compositions and methods of use thereof
WO2001046127A1 (fr) 1999-12-22 2001-06-28 Om Pharma Pseudodipeptides acyles porteurs d'un bras auxiliaire fonctionnalise
US6764685B1 (en) 2000-03-21 2004-07-20 Medimmune Vaccines, Inc. Recombinant parainfluenza virus expression systems and vaccines
ES2252261T3 (es) 2000-06-28 2006-05-16 Glycofi, Inc. Metodos para producir glicoproteinas modificadas.
US20030232061A1 (en) 2001-10-18 2003-12-18 Fouchier Ronaldus Adrianus Maria Recombinant parainfluenza virus expression systems and vaccines comprising heterologous antigens derived from metapneumovirus
US20040096451A1 (en) 2002-07-25 2004-05-20 Young James F. Methods of treating and preventing RSV, hMPV, and PIV using anti-RSV, anti-hMPV, and anti-PIV antibodies
ATE489968T1 (de) 2001-03-09 2010-12-15 Id Biomedical Corp Quebec Proteosom-liposaccharid-vakzine-adjuvans
KR100892614B1 (ko) 2001-04-17 2009-04-09 다이닛본 스미토모 세이야꾸 가부시끼가이샤 신규 아데닌 유도체
JP2005503797A (ja) 2001-09-13 2005-02-10 ジェンベク、インコーポレイティッド アデノウイルスベクター及び関連する系、並びに製造及び使用の方法
WO2003029416A2 (en) 2001-10-01 2003-04-10 Uab Research Foundation Recombinant respiratory syncytial viruses with deleted surface glycoprotein genes and uses thereof
ES2318615T3 (es) 2001-11-16 2009-05-01 Coley Pharmaceutical Group, Inc. N-(4-(4-amino-2-etil-1h-imidazo(4,5-c)quinolin-1-il)butil)metanosulfonamida, una composicion farmaceutica que la comprende y uso de la misma.
CA2743750A1 (en) 2002-02-21 2003-09-04 Medimmune, Llc Recombinant parainfluenza virus expression systems and vaccines comprising heterologous antigens derived from respiratory syncytial virus
EP1558747B1 (en) 2002-10-16 2009-10-14 The Scripps Research Institute Glycoprotein synthesis
JP2006517974A (ja) 2003-02-13 2006-08-03 スリーエム イノベイティブ プロパティズ カンパニー Ｉｒｍ化合物およびトル様受容体８に関する方法および組成物
KR20110097971A (ko) 2003-04-25 2011-08-31 메디뮨 백신즈, 인코포레이티드 메타뉴모바이러스 유래 이종 항원을 포함하는 재조합 파라인플루엔자 바이러스 발현 시스템 및 백신
US7704720B2 (en) 2003-04-25 2010-04-27 Medimmune, Llc Metapneumovirus strains and their use in vaccine formulations and as vectors for expression of antigenic sequences and methods for propagating virus
US8637234B2 (en) 2004-04-16 2014-01-28 Uab Research Foundation Molecular scaffolds for HIV-1 epitopes
WO2006091455A2 (en) 2005-02-18 2006-08-31 Uab Research Foundation Molecular scaffolds for hiv-1 immunogens
JP2008537482A (ja) 2005-03-10 2008-09-18 メッドイミューン バクシーンズ，インコーポレイティド メタニューモウイルス株、およびワクチン製剤におけるその使用および抗原配列発現用ベクターとしてのその使用、ならびにウイルスの増殖法
US7728106B2 (en) 2005-07-01 2010-06-01 University Of Maryland Biotechnology Institute HIV-1 glycopeptides and derivatives; preparation and applications thereof
EP2001358B1 (en) 2006-03-27 2016-07-13 University Of Maryland, Baltimore Glycoprotein synthesis and remodeling by enzymatic transglycosylation
EP2062180A2 (en) 2006-08-25 2009-05-27 The Government of the United States of America as Represented by The Department of Health and Human Services Epitope-protein scaffolds and their use
EP1997830A1 (en) 2007-06-01 2008-12-03 AIMM Therapeutics B.V. RSV specific binding molecules and means for producing them
US20090017517A1 (en) 2007-07-13 2009-01-15 Medimmune, Llc Preparation of Negative-Stranded RNA Viruses by Electroporation
EA021393B1 (ru) * 2007-12-24 2015-06-30 Глаксосмитклайн Байолоджикалс С.А. Рекомбинантные антигены rsv
CA2744910C (en) 2007-12-27 2018-01-30 Universitaet Zuerich Replication-defective arenavirus vectors
US20110318376A1 (en) * 2008-12-24 2011-12-29 University Of Rochester Recombinant expression of self-folding neutralizing epitope-bearing subdomains of the respiratory syncytial virus attachment and fusion proteins
WO2010130756A1 (en) 2009-05-12 2010-11-18 Transgene Sa Immortalized avian cell lines and use thereof
US8889146B2 (en) * 2009-06-24 2014-11-18 Glaxosmithkline Biologicals, Sa Vaccine
MX2012000035A (es) * 2009-06-24 2012-02-28 Id Biomedical Corp Quebec Antigenos de virus de sincicio respiratorio recombinantes.
AR077757A1 (es) * 2009-07-15 2011-09-21 Novartis Ag Composiciones de proteinas de fusion del virus sincicial respiratorio (rsv) y metodos para su preparacion
US8568726B2 (en) 2009-10-06 2013-10-29 Medimmune Limited RSV specific binding molecule
NZ599148A (en) 2009-10-06 2014-08-29 Medimmune Ltd Rsv-specific binding molecule
US20120315270A1 (en) 2009-10-21 2012-12-13 The United States Of America, As Represented By The Rsv immunogens, antibodies and compositions thereof
HUE034673T2 (hu) * 2011-05-13 2018-02-28 Glaxosmithkline Biologicals Sa Pre-fúziós Rsv F antigének
CN102210860B (zh) 2011-05-31 2012-11-21 昆明理工大学 一种结核分枝杆菌tb10．4-f1融合蛋白疫苗及制备方法
ES2395677B1 (es) * 2011-07-29 2013-12-26 Instituto De Salud Carlos Iii Proteína F del VRSH en conformación pre-fusión estabilizada y anticuerpos neutralizantes específicos frente a la misma.
SG11201500573RA (en) * 2012-08-06 2015-02-27 Glaxosmithkline Biolog Sa Method for eliciting in infants an immune response against rsv and b. pertussis
EA201590683A1 (ru) * 2012-11-20 2015-11-30 Глаксосмитклайн Байолоджикалс С.А. Тримеры rsv f, предшествующие слиянию
US9738689B2 (en) 2013-03-13 2017-08-22 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Prefusion RSV F proteins and their use
HUE067333T2 (hu) * 2013-03-13 2024-10-28 The United States Of America As Represented By Prefúziós RSV F fehérjék és ezek felhasználása
CA2906960C (en) 2013-03-15 2021-07-20 Xiamen University Epitope of rsv fusion protein and antibody recognizing the epitope
JP6469081B2 (ja) 2013-04-25 2019-02-13 ヤンセン ファッシンズ アンド プリベンション ベーフェーＪａｎｓｓｅｎ Ｖａｃｃｉｎｅｓ ＆ Ｐｒｅｖｅｎｔｉｏｎ Ｂ．Ｖ． 安定化された可溶性融合前ｒｓｖｆポリペプチド

Also Published As

Publication number Publication date
KR102450375B1 (ko) 2022-10-04
AU2018282476B2 (en) 2020-12-10
CN105473604A (zh) 2016-04-06
LT2970398T (lt) 2024-08-12
PL2970398T3 (pl) 2024-09-16
US20180319846A1 (en) 2018-11-08
US20160046675A1 (en) 2016-02-18
CN105473604B (zh) 2021-01-22
KR20220139415A (ko) 2022-10-14
US20220002351A1 (en) 2022-01-06
BR112015022375A8 (pt) 2018-01-23
PT2970398T (pt) 2024-06-07
SI2970398T1 (sl) 2024-09-30
KR102766946B1 (ko) 2025-02-12
US11981707B2 (en) 2024-05-14
HRP20240996T1 (hr) 2024-10-25
CA2902877A1 (en) 2014-10-02
AU2014243756A1 (en) 2015-09-17
RU2015142981A (ru) 2017-04-17
WO2014160463A1 (en) 2014-10-02
JP2024107243A (ja) 2024-08-08
EP4421177A3 (en) 2024-12-18
FI2970398T3 (fi) 2024-08-06
US11130785B2 (en) 2021-09-28
KR20150127102A (ko) 2015-11-16
WO2014160463A8 (en) 2015-10-08
BR112015022375A2 (pt) 2017-10-10
JP7503588B2 (ja) 2024-06-20
JP2016519658A (ja) 2016-07-07
RU2761631C2 (ru) 2021-12-13
ES2981623T3 (es) 2024-10-10
DK2970398T3 (da) 2024-08-05
JP2020089384A (ja) 2020-06-11
EP2970398A4 (en) 2016-08-24
EP4421177A2 (en) 2024-08-28
MX2021010519A (es) 2021-10-01
AU2023200712A1 (en) 2023-03-09
JP7043530B2 (ja) 2022-03-29
RS65760B1 (sr) 2024-08-30
CN112851766A (zh) 2021-05-28
RU2021132097A (ru) 2022-03-03
JP2022089818A (ja) 2022-06-16
AU2023200712B2 (en) 2025-02-20
EP2970398A1 (en) 2016-01-20
AU2021201468B2 (en) 2022-11-24
JP6703475B2 (ja) 2020-06-03
MX2015013065A (es) 2016-06-06
AU2018282476A1 (en) 2019-01-24
AU2014243756B2 (en) 2018-09-27
EP2970398B1 (en) 2024-05-08
US10017543B2 (en) 2018-07-10
SMT202400297T1 (it) 2024-09-16
RU2015142981A3 (hu) 2018-03-14
AU2021201468A1 (en) 2021-03-25
US20240018193A1 (en) 2024-01-18

Similar Documents

Publication Publication Date Title
IL276106A (en) Garp-binding proteins and their uses
PT2970398T (pt) Proteínas f de pré-fusão do vsr e sua utilização
IL261743B (en) and their uses 33–il antibodies against
ZA201601430B (en) Insecticidal proteins and methods for their use
IL245040B (en) Antibodies against pdgfr-beta and their uses
ZA201509369B (en) Insecticidal proteins and methods for their use
IL243974B (en) Antibodies against –prlr and uses
IL240034A0 (en) Chimeric proteins based on l1–pd and –pd–l2 and their uses
SG11201509618QA (en) Anti-b7-h5 antibodies and their uses
SG10201708143QA (en) Anti-c10orf54 antibodies and uses thereof
HK1220379A1 (zh) 抗鐵調素抗體及其用途
IL245991A0 (en) 4 Amino-6-(substituted-alkyl-halo)-picolinates and their use as herbicides
IL240177A (en) Chromium-6-Iloxy-cycloalkanes are conserved and used as drugs
EP3029071A4 (en) Saxatilin-fc fusion protein and use thereof
AU2013901331A0 (en) Fusion Proteins and Use Thereof
GB201320209D0 (en) Improvements in or relating to protein Micro-nets